Anemia, Sickle Cell Clinical Trial
Official title:
Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Study
Sickle cell anemia (SCA) is an inherited blood disorder that can cause organ damage. The BABY HUG study is evaluating the use of the medication hydroxyurea at preventing organ damage in children with SCA. The purpose of this follow-up study is to evaluate the long-term effects of hydroxyurea in children who have participated in the BABY HUG study.
SCA is an inherited blood disorder in which the body makes sickle-shaped red blood cells that
contain abnormal hemoglobin. The sickled cells block blood flow in the vessels that lead to
limbs and organs. This can cause pain, serious infections, and organ damage. The BABY HUG
study (NCT00006400) is examining whether the medication hydroxyurea can prevent organ damage,
especially in the spleen and kidneys, in children with SCA. This study is a follow-up study
to the BABY HUG study and will enroll children who have participated in the BABY HUG study.
The purpose of this study is to examine the long-term effects of using hydroxyurea as a
treatment for SCA, including both the risks and benefits. Study researchers will also
investigate the optimal age to begin treatment with hydroxyurea in children with SCA.
This study will enroll children between 2 and 7 years old who participated in the BABY HUG
study. Hydroxyurea will not be provided to participants as part of this study, but
participants may receive the medication from their own doctors. Parents of participants can
choose for their child to participate in this study in one of two ways-by enrolling in either
a passive follow-up group or an active follow-up group. For participants in the passive
follow-up group, study researchers will review participants' medical records every 6 months,
in addition to reviewing brain ultrasound tests and computed tomography (CT) or magnetic
resonance imaging (MRI) scans, if completed. Participants will have a blood and urine
collection at baseline and Year 4 (or at the end of the study, whichever comes first).
Participants in the active follow-up group will take part in the same study procedures as
participants in the passive follow-up group. In addition, at Year 2, participants in this
group will undergo an additional blood and urine collection, a scanning procedure to obtain
images of the liver and spleen, a kidney test, neuropsychological testing, and an ultrasound
imaging test to evaluate liver and spleen size.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06078696 -
Siplizumab for Sickle Cell Disease Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02561312 -
Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
|
||
Completed |
NCT00059293 -
Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
|
||
Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
Completed |
NCT00005277 -
Cooperative Study of The Clinical Course of Sickle Cell Disease
|
N/A | |
Active, not recruiting |
NCT04170348 -
Daily Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
Completed |
NCT04584528 -
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
|
N/A | |
Recruiting |
NCT02286154 -
Therapeutic Response Evaluation and Adherence Trial (TREAT)
|
N/A | |
Completed |
NCT02857023 -
Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease
|
N/A | |
Withdrawn |
NCT01925001 -
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
|
Phase 2 | |
Terminated |
NCT00122980 -
Stroke With Transfusions Changing to Hydroxyurea
|
Phase 3 | |
Completed |
NCT00246077 -
Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport
|
N/A | |
Completed |
NCT00094887 -
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
|
Phase 2 | |
Completed |
NCT00035763 -
Pain in Sickle Cell Epidemiologic Study
|
N/A | |
Terminated |
NCT04091737 -
CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT00005300 -
Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease
|
N/A | |
Recruiting |
NCT04351698 -
SMILES: Study of Montelukast in Sickle Cell Disease
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06290401 -
A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
|
Phase 2 | |
Recruiting |
NCT05087303 -
Telemedicine for Children With Sickle Cell Disease
|
N/A |